Belite Bio (NASDAQ:BLTE) Announces Quarterly Earnings Results

Posted by George Bondi on May 20th, 2026

Belite Bio (NASDAQ:BLTE – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.26, FiscalAI reports.

Belite Bio Stock Down 2.2%

BLTE opened at $139.70 on Wednesday. The firm has a 50-day simple moving average of $161.30 and a two-hundred day simple moving average of $156.16. Belite Bio has a 52 week low of $56.10 and a 52 week high of $200.00. The company has a market capitalization of $5.58 billion, a PE ratio of -60.74 and a beta of -1.19.

Insider Activity at Belite Bio

In other Belite Bio news, CEO Yu-Hsin Lin sold 9,200 shares of the stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $181.45, for a total transaction of $1,669,340.00. Following the completion of the transaction, the chief executive officer owned 170,934 shares of the company’s stock, valued at $31,015,974.30. This represents a 5.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Wan-Shan Chen sold 1,100 shares of the stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $180.43, for a total transaction of $198,473.00. Following the transaction, the director directly owned 9,096 shares of the company’s stock, valued at $1,641,191.28. This trade represents a 10.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 26,166 shares of company stock worth $4,548,351 over the last 90 days. Company insiders own 13.29% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Belite Bio by 28,200.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock valued at $45,000 after purchasing an additional 282 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Belite Bio by 28.1% in the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock valued at $87,000 after acquiring an additional 257 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in shares of Belite Bio in the 4th quarter valued at about $108,000. EverSource Wealth Advisors LLC bought a new position in shares of Belite Bio in the 2nd quarter valued at about $147,000. Finally, BNP Paribas Financial Markets bought a new position in shares of Belite Bio in the 2nd quarter valued at about $190,000. Institutional investors own 0.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on BLTE shares. Bank of America started coverage on shares of Belite Bio in a report on Monday, January 26th. They set a “buy” rating and a $195.00 target price for the company. Cantor Fitzgerald boosted their price objective on shares of Belite Bio from $200.00 to $266.00 and gave the stock an “overweight” rating in a report on Tuesday, March 3rd. Mizuho set a $223.00 price objective on shares of Belite Bio in a report on Thursday, February 19th. Wall Street Zen upgraded shares of Belite Bio from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Finally, Morgan Stanley boosted their price objective on shares of Belite Bio from $191.00 to $201.00 and gave the stock an “overweight” rating in a report on Tuesday, March 3rd. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Belite Bio presently has a consensus rating of “Moderate Buy” and a consensus price target of $202.33.

Get Our Latest Stock Analysis on Belite Bio

About Belite Bio

(Get Free Report)

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.